Intercell enters into strategic partnership with Wyeth for the use of its IC31TM adjuvant in various infectious disease vaccines

14-Sep-2006

Intercell AG announced that it has closed a worldwide nonexclusive agreement under which Wyeth has the right to use Intercell's fully synthetic novel adjuvant IC31TM in various selected infectious disease vaccine programs. Under the agreement, Intercell may be entitled to receive up to USD 77 million in upfront, option and milestone payments as well as royalties on product net sales.

Vaccines, based on antigens alone, are not sufficient to provide full protection. Adjuvants are needed to educate the immune system to recognize and eliminate the pathogens efficiently. IC31TM is an adjuvant that induces Tcell and Bcell responses by using a unique synthetic formulation which combines the immunostimulating properties of an antimicrobial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens; no conjugation is required.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances